Heartburn Medication Recall 2020: Ranitidine Recalls Continue Over Cancer-Causing Ingredient

After several retailers pulled heartburn medications from their store shelves because they may have a cancer-causing ingredient, another recall has been issued for the drug ranitidine by Appco Pharma LLC.

The recall includes both 150 and 300 mg prescription-only ranitidine hydrochloride capsules that are used in the treatment of duodenal ulcers, benign gastric ulcers, reflux-esophagitis, post-operative peptic ulcers, Zollinger-Ellison Syndrome, and other conditions to reduce gastric secretion and acid indigestion.

The recalled heartburn medication may have N-nitrosodimethylamine (NDMA) – a cancer-causing ingredient – above the acceptable levels established by the U.S. Food and Drug Administration.

The recalled ranitidine capsules were packaged in bottles and can be identified by checking the product name, bottle count, manufacturer details, and batch or lot number located on the medication. The affected medication was distributed nationwide. A full list of medication included in this recall can be viewed here.

Consumers that have been prescribed the affected heartburn medication should stop using the product. They should return it to the place of purchase and contact their physician or pharmacist for an alternative treatment plan.

Questions about the recall can be directed to Appco at 732-253-7735, Monday through Friday from 8 a.m. to 6 p.m. EST or by email at pv@appcopharma.com. ANI Pharmaceutical, Appco’s marketing partner, can be contacted at 1-800-308-6755 or via email at PVSupport@safetycall.com.

Appco has not received any reports of adverse reactions from the recalled ranitidine capsules. Consumers that have any problems related to taking the affected medication should contact their healthcare provider.